Molecular structure of Rimonabant, CAS Number: 168273-06-1
Rimonabant (CAS 168273-06-1)
See product citations (15)
Alternate Names:
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidino-1H-pyrazole-3-carboxamide
Application:
Rimonabant is an immunomodulatory CB1 receptor inverse agonist
CAS Number:
168273-06-1
Purity:
≥98%
Molecular Weight:
463.79
Molecular Formula:
C22H21Cl3N4O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Rimonabant, also known as SR141716, was the first selective CB1 (cannabinoid 1) central receptor inverse agonist (Ki = 1.8 nM). It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects. In rodent models and clinical trials, rimonabant effectively induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios. However, rimonabant reportedly produces adverse psychiatric and neurological effects (e.g., depression or anxiety) and therefore is not approved by the FDA for use as a weight control medication. Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.
Rimonabant (CAS 168273-06-1) References
- Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. | Cani, PD., et al. 2004. Br J Nutr. 92: 757-61. PMID: 15533263
- The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. | Jbilo, O., et al. 2005. FASEB J. 19: 1567-9. PMID: 16009704
- The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. | Gary-Bobo, M., et al. 2006. Mol Pharmacol. 69: 471-8. PMID: 16282221
- SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. | Wilson, DM., et al. 2006. Pharmacol Biochem Behav. 85: 105-13. PMID: 16934319
- The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. | Niyuhire, F., et al. 2007. Psychopharmacology (Berl). 191: 223-31. PMID: 17211653
- Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. | Pattij, T., et al. 2007. Psychopharmacology (Berl). 193: 85-96. PMID: 17387457
- The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. | Melis, T., et al. 2007. Neurosci Lett. 419: 231-5. PMID: 17462824
- The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. | Schäfer, A., et al. 2008. Br J Pharmacol. 154: 1047-54. PMID: 18469848
- Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A). | Diergaarde, L., et al. 2008. Neuropharmacology. 55: 712-6. PMID: 18588903
- The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. | Esposito, I., et al. 2008. Mol Pharmacol. 74: 1678-86. PMID: 18801918
- Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. | Dol-Gleizes, F., et al. 2009. Arterioscler Thromb Vasc Biol. 29: 12-8. PMID: 18845788
- The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. | Verty, AN., et al. 2009. Obesity (Silver Spring). 17: 254-61. PMID: 19057531
- The structure of Rimonabant in the solid state and in solution: an experimental and theoretical study. | Alkorta, I., et al. 2009. Eur J Med Chem. 44: 1864-9. PMID: 19081653
- The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. | Ward, SJ., et al. 2009. Drug Alcohol Depend. 105: 248-55. PMID: 19679410
- Cannabinoid receptor type-1 partially mediates metabolic endotoxemia-induced inflammation and insulin resistance. | Grunewald, ZI., et al. 2019. Physiol Behav. 199: 282-291. PMID: 30502357
Inhibitor of:
ABHD6, ACOT10, ACOT12, ACOT3, ACOT8, CB1, CBG, CNR1, CNRIP1, D-GPCR, Fat, Gm436, GPR18, NAPE-PLD, Olfr315, Olfr356, Olfr380, Olfr438, Olfr455, Olfr49, Olfr490, Olfr539, Olfr987, Olfr99, OR10K2, pro-MCH, T1R2, V1RB4, Vmn2r29, Vmn2r51, Vmn2r80, and Vmn2r95.Activator of:
CB1, CNR1, GH, LYPD6, mMgl1, and MrgB3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rimonabant, 5 mg | sc-205491 | 5 mg | $72.00 | |||
Rimonabant, 10 mg | sc-205491A | 10 mg | $160.00 |